Quantifying infection risks in incompatible living donor kidney transplant recipients

Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/compatible (n = 260), low (0-4 plasmaphereses, n = 47), moderate (5-9, n = 74), and high (>= 10, n = 94). The 1-year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high-intensity desensitization (P < .001). The most common infections were UTI (33.5% of ILDKT vs. 21.5% compatible), opportunistic (21.9% vs. 10.8%), and bloodstream (19.1% vs. 5.4%) (P < .001). In weighted models, a trend toward increased risk was seen in low (wIRR = (0.77)1.40(2.56),P = .3) and moderately (wIRR = (0.88)1.35(2.06),P = .2) desensitized recipients, with a statistically significant 2.22-fold (wIRR = (1.33)2.22(3.72),P = .002) increased risk in highly desensitized recipients. Recipients with >= 4 infections were at higher risk of prolonged hospitalization (wIRR = (2.62)3.57(4.88), P < .001) and death-censored graft loss (wHR = (1.15)4.01(13.95),P = .03). Post-KT infections are more common in desensitized ILDKT recipients. A subset of highly desensitized patients is at ultra-high risk for infections. Strategies should be designed to protect patients from the morbidity of recurrent infections, and to extend the survival benefit of ILDKT across the spectrum of recipients.

Automated summary

Desensitization for incompatible living donor kidney transplantation increases the risk of infections, especially in highly desensitized recipients, leading to prolonged hospitalization and graft loss. Strategies are needed to protect patients from recurrent infections and extend the survival benefit of ILDKT.